Safe & Easy for Alzheimer's Disease and Related Pathologies
- Conditions
- Cognitive Deterioration
- Interventions
- Other: Patient's answer with non pharmacological therapeutic
- Registration Number
- NCT02518243
- Lead Sponsor
- Centre Hospitalier Universitaire de Nice
- Brief Summary
All over the world the increasing prevalence of chronic disorders and its impact on functional decline is challenging the sustainability of health care systems. Older individuals also frequently experience the reversible "frailty syndrome", which overlaps with chronic diseases, increasing incidence of disability.
Building a global system aiming to take in charge all causes leading to loss of autonomy is a rather complicated task involving numerous Information and Communication technologies (ICT) solutions which are not always easy to use in everyday life.
The SafEE (Safe Easy Environment) project aim is to improve the safety, autonomy and quality of life of older people at risk.
The SafEE2 project develop non pharmacological therapeutic through diferent ICT (stimulation aromatherapy automatic fragrance ...) .
The goal of this study is to validate the acceptability, sensitivity and efficacy of the systems.
- Detailed Description
The non pharmacological therapeutic will be install at hospital room :
* aromatherapy,
* music therapy,
* cognitive training in multimedia application offering cognitive games.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 7
- Subjects with a diagnosis of Alzheimer's disease according to NINCDS-ADRDA (McKhann, Drachman et al. 1984) or typical or atypical Alzheimer's disease (Dubois B. et al. 2007).
- Score at Mini Mental Test (MMSE) ≥16.
- Subjects residing in nursing homes.
- Subjects beneficiaries of a social security scheme.
- Signature of free and informed consent.
- Failure to pass the neuropsychological tests because of a sensory or motor deficit.
- Sensory deficit (olfactory or visual) preventing the patient made perfectly meet the therapeutic solutions.
- Prescription of a new treatment psychotropic (hypnotic, anxiolytic, antidepressant, antipsychotic) in the week before the evaluation;
- Persons deprived of liberty (administrative or judicial).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Alzheimer's Disease Patient's answer with non pharmacological therapeutic -
- Primary Outcome Measures
Name Time Method Tolerance of the systems set up and use frequency evaluated using the Caregiver Questionnaire 3 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Ehpad Valrose
🇫🇷Nice, France